News & Updates
Filter by Specialty:
ARBs a good alternative to ACEIs in patients with acute MI
The incidence of death is comparable between patients with acute myocardial infarction (MI) without heart failure (HF) receiving angiotensin II receptor blockers (ARBs) and those taking angiotensin-converting enzyme inhibitors (ACEIs), a study has shown.
ARBs a good alternative to ACEIs in patients with acute MI
20 Nov 2024
SGLT-2 inhibitors help avert death in patients with HFrEF
Use of SGLT-2 inhibitors may reduce the risk of all-cause and cardiovascular (CV) mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), reports a study.
SGLT-2 inhibitors help avert death in patients with HFrEF
19 Nov 2024
Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk
Treatment with trastuzumab deruxtecan (T-DXd) demonstrates efficacy in patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer but may result in adverse events, such as interstitial lung disease (ILD), suggests a study.
Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk
18 Nov 2024
Sacituzumab govitecan improves survival in advanced breast cancer
Treatment with sacituzumab govitecan (SG), a novel antibody-drug conjugate, provides survival benefits in women diagnosed with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer, reports a study.
Sacituzumab govitecan improves survival in advanced breast cancer
18 Nov 2024
Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma
Patients with stage III melanoma show inconsistent use of adjuvant immunotherapy despite its survival benefits, according to a study.